Related Experiment Video

Updated: Jul 4, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

The use of beta-blockers to decrease adverse perioperative cardiac events

Debora L Ryder1

  • 1Postanesthesia Care Unit, Morton Plant North Bay Hospital, USA. Debora.ryder@baycare.org

Dimensions of Critical Care Nursing : DCCN
|May 31, 2008
PubMed

Insights

Elderly patients undergoing surgery face high risks of myocardial ischemia, a serious cardiac complication. Underused beta-blockers could reduce this risk, necessitating a multidisciplinary approach for perioperative cardiac care.

Area of Science:

  • Geriatric Medicine
  • Cardiology
  • Anesthesiology

Background:

  • Aging populations lead to increased surgeries in high-risk individuals.
  • Perioperative myocardial ischemia presents a significant mortality risk (70%) in surgical patients.
  • Complex patient factors include atypical presentations, pain, and analgesic effects.

Purpose of the Study:

  • To highlight the critical role of critical care nurses in managing perioperative risks.
  • To emphasize the underutilization of beta-blockers in preventing myocardial ischemia.
  • To advocate for a multidisciplinary strategy for optimal beta-blocker use in elderly surgical patients.

Main Methods:

  • Review of perioperative patient complexity and risk factors.
  • Analysis of myocardial ischemia incidence and mortality.
  • Assessment of beta-blocker efficacy and current usage patterns.

Main Results:

  • Myocardial ischemia is a major cause of perioperative complications and mortality.
  • Beta-blockers show potential in reducing myocardial ischemia risk.
  • Current use of beta-blockers in this population is suboptimal.

Conclusions:

  • A multidisciplinary approach is essential for effective perioperative cardiac risk management.
  • Optimizing beta-blocker therapy can mitigate cardiac complications in elderly surgical patients.
  • Improved nursing assessment and intervention are crucial for patient safety.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...